[Seite 28↓]

Literaturverzeichnis

[1] Virchow, R (1983): Der medicinische Universitaets-Unterricht, Die medicinische Reform. Eine Wochenschrift, erschienen vom 10. Juli 1848 bis zum 29.Juni 1849 , Reprint. Auflage, Seite 85-87, Akademie-Verlag, Berlin.

[2] Berger, M; Richter, B und Mühlhauser, J (1997): Evidence-based Medicine. Eine Medizin auf rationaler Grundlage, Internist (Band 38), Seite 344-351.

[3] Martini, P (1953): Methodenlehre der therapeutisch-klinischen Forschung, Springer, Berlin.

[4] Abel, U und Koch, A (1997): Randomisation in klinischen Studien. Empirisch begründet oder nur ein Dogma?, Internist (Band 38), Seite 318-324.

[5] Raspe, H (1996): Evidence based medicine: Modischer Unsinn, alter Wein in neuen Schläuchen oder aktuelle Notwendigkeit?, Z.aerztl.Fortbild. (Band 90), Seite 553-562.

[6] The Cardiac Arrhythmia Pilot Study (CAPS) Investigators (1988): Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS, Am.J.Cardiol. (Band 61), Seite 501-509.

[7] The Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989): Preliminary report: Effect of Encainide and Flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction, N.Engl.J.Med. (Band 321), Seite 406-412.

[8] Clancy, CM und Kamerow, DB (1996): Evidence-based medicine meets cost-effectiveness analysis, J.Am.Med.Assoc. (Band 276), Seite 329-330.

[9] Evidence-Based Medicine Working Group (1992): Evidence-based medicine - a new approach to teaching the practice of medicine, J.Am.Med.Assoc. (Band 268), Seite 2420-2425.

[10] Kunz, R. und Fritsche, L. (2000): [Evidence-based medicine--from evidence production to its implementation], Z.Rheumatol. (Band 59), Nr. 1, Seite 38-40. URL: PM:10769422

[11] Moher, D.; Schulz, K. F. und Altman, D. G. (2001): The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials, Ann.Intern.Med. (Band 134), Nr. 8, Seite 657-662. URL: PM:11304106

[12]2003

[13] Sackett, DL; Haynes, RB; Guyatt, GH und Tugwell, P (1985): Clinical epidemiology: A basic science for clinical medicine, Little Brown and Co. Inc., Boston.

[14] Parkes, J.; Hyde, C.; Deeks, J. und Milne, R. (2001): Teaching critical appraisal skills in health care settings, Cochrane.Database.Syst.Rev., Nr. 3, Seite CD001270. URL: PM:11686986

[15] Kunz, R.; Fritsche, L. und Neumayer, H. H. (2001): [Development of quality assurance criteria for continuing education in evidence-based medicine], Z.Arztl.Fortbild.Qualitatssich. (Band 95), Nr. 5, Seite 371-375. URL: PM:11486502

[16]Antes, G; Donner-Banzhoff, N; Dreykluft, R; Eberlein-Gonska, M; Falck-Ytter, Y; and Gibis, B (2004)

[17] Hannan, E. L.; Racz, M. J.; Jollis, J. G. und Peterson, E. D. (1997): Using Medicare claims data to assess provider quality for CABG surgery: does it work well enough?, Health Serv.Res. (Band 31), Nr. 6, Seite 659-678. URL: PM:9018210


[Seite 29↓]

[18] Fine, L. G.; Keogh, B. E.; Cretin, S.; Orlando, M. und Gould, M. M. (2003): How to evaluate and improve the quality and credibility of an outcomes database: validation and feedback study on the UK Cardiac Surgery Experience, BMJ (Band 326), Nr. 7379, Seite 25-28. URL: PM:12511458

[19] Kaplan, B.; Schold, J. und Meier-Kriesche, H. U. (2003): Overview of large database analysis in renal transplantation, Am.J.Transplant. (Band 3), Nr. 9, Seite 1052-1056. URL: PM:12919083

[20] Bickell, N. A. und Chassin, M. R. (2000): Determining the quality of breast cancer care: do tumor registries measure up?, Ann.Intern.Med. (Band 132), Nr. 9, Seite 705-710. URL: PM:10787363

[21] Tang, P. C.; LaRosa, M. P. und Gorden, S. M. (1999): Use of computer-based records, completeness of documentation, and appropriateness of documented clinical decisions, J.Am.Med.Inform.Assoc. (Band 6), Nr. 3, Seite 245-251. URL: PM:10332657

[22] Black, N. (1999): High-quality clinical databases: breaking down barriers, Lancet (Band 353), Nr. 9160, Seite 1205-1206. URL: PM:10217078

[23] Fritsche, L; Lindemann-vonTrzebiatowski, G und Schröter, K (1998): TBase2 - Eine Internet-basierte Transplantationsdatenbank, Humboldt-Spektrum, Nr. 1/98, Seite 58-61.

[24] Fritsche, L; Schröter, K; Lindemann, G; Kunz, R; Budde, K und Neumayer, H-H (2000): A Web-Based Electronic Patient Record System as a Means for Collection of Clinical Data, Lecture Notes in Computer Science (Band 1933), Seite 198-205.

[25] Smits, J. M.; Persijn, G. G.; van Houwelingen, H. C.; Claas, F. H. und Frei, U. (2002): Evaluation of the Eurotransplant Senior Program. The results of the first year, Am.J.Transplant. (Band 2), Nr. 7, Seite 664-670. URL: PM:12201369

[26] De Meester, J.; Persijn, G. G.; Wujciak, T.; Opelz, G. und Vanrenterghem, Y. (1998): The new Eurotransplant Kidney Allocation System: report one year after implementation. Eurotransplant International Foundation, Transplantation (Band 66), Nr. 9, Seite 1154-1159. URL: PM:9825810

[27] Bradley, B. A. (2000): Does the risk of acute rejection really decrease with increasing recipient age?, Transpl.Int. (Band 13 Suppl 1), Seite S42-S44. URL: PM:11111959

[28] Tullius, S. G.; Reutzel-Selke, A.; Egermann, F.; Nieminen-Kelha, M.; Jonas, S.; Bechstein, W. O.; Volk, H. D. und Neuhaus, P. (2000): Contribution of prolonged ischemia and donor age to chronic renal allograft dysfunction, J.Am.Soc.Nephrol. (Band 11), Nr. 7, Seite 1317-1324. URL: PM:10864589

[29] Black, N. (1996): Why we need observational studies to evaluate the effectiveness of health care, BMJ (Band 312), Nr. 7040, Seite 1215-1218. URL: PM:8634569

[30]US Food and Drug Administration, Center for Drug Evaluation and Research (2004)

[31]EMEA (2004)

[32] MacDonald, A. S. (2001): A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts, Transplantation (Band 71), Nr. 2, Seite 271-280. URL: PM:11213073

[33] Kahan, B. D. (2000): Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group, Lancet (Band 356), Nr. 9225, Seite 194-202. URL: PM:10963197

[34] Kahan, B. D.; Julian, B. A.; Pescovitz, M. D.; Vanrenterghem, Y. und Neylan, J. (1999): Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group, Transplantation (Band 68), Nr. 10, Seite 1526-1532. URL: PM:10589950


[Seite 30↓]

[35] Kahan, B. D.; Welsh, M. und Rutzky, L. P. (1995): Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring, Ther.Drug Monit. (Band 17), Nr. 6, Seite 621-624. URL: PM:8588231

[36] Mahalati, K.; Belitsky, P.; Sketris, I.; West, K. und Panek, R. (1999): Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation, Transplantation (Band 68), Nr. 1, Seite 55-62. URL: PM:10428267

[37] (2002): Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation, Am.J.Transplant. (Band 2), Nr. 2, Seite 148-156. URL: PM:12099517

[38] Armstrong, V. W. und Oellerich, M. (2001): New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine, Clin.Biochem. (Band 34), Nr. 1, Seite 9-16. URL: PM:11239509

[39] Campbell, S. B. und Johnson, D. W. (2003): Patient management by cyclosporine C2 monitoring: not enough science yet to justify the practice, Transplantation (Band 75), Nr. 11, Seite 1917-1918. URL: PM:12811260

[40] Halloran, P.; Mathew, T.; Tomlanovich, S.; Groth, C.; Hooftman, L. und Barker, C. (1997): Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups, Transplantation (Band 63), Nr. 1, Seite 39-47. URL: PM:9000658

[41] Allison, A. C. und Eugui, E. M. (2000): Mycophenolate mofetil and its mechanisms of action, Immunopharmacology (Band 47), Nr. 2-3, Seite 85-118. URL: PM:10878285

[42] Fulton, B. und Markham, A. (1996): Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation, Drugs (Band 51), Nr. 2, Seite 278-298. URL: PM:8808168

[43] Mourad, M.; Malaise, J.; Chaib, Eddour D.; De Meyer, M.; Konig, J.; Schepers, R.; Squifflet, J. P. und Wallemacq, P. (2001): Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation, Clin.Chem. (Band 47), Nr. 7, Seite 1241-1248. URL: PM:11427455

[44] Pelletier, R. P.; Akin, B.; Henry, M. L.; Bumgardner, G. L.; Elkhammas, E. A.; Rajab, A. und Ferguson, R. M. (2003): The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation, Clin.Transplant. (Band 17), Nr. 3, Seite 200-205. URL: PM:12780668

[45] Glander, P.; Hambach, P.; Braun, K. P.; Fritsche, L.; Waiser, J.; Mai, I.; Neumayer, H. H. und Budde, K. (2003): Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients, Int.J.Clin.Pharmacol.Ther. (Band 41), Nr. 10, Seite 470-476. URL: PM:14703953

[46] Tu, J. V. (1996): Advantages and disadvantages of using artificial neural networks versus logistic regression for predicting medical outcomes, J.Clin.Epidemiol. (Band 49), Nr. 11, Seite 1225-1231. URL: PM:8892489

[47] Mitchell, T (1997): Machine Learning, McGraw Hill, New York.

[48] Fritsche, L.; Schlaefer, A.; Budde, K.; Schroeter, K. und Neumayer, H. H. (2001): Case-based reasoning algorithm for kidney transplant monitoring, Transplant.Proc. (Band 33), Nr. 7-8, Seite 3331-3333. URL: PM:11750424


[Seite 31↓]

[49] Lamas, G. A.; Pfeffer, M. A.; Hamm, P.; Wertheimer, J.; Rouleau, J. L. und Braunwald, E. (1992): Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators, N.Engl.J.Med. (Band 327), Nr. 4, Seite 241-247. URL: PM:1535419

[50] Fritsche, L, Einecke, G, Fleiner, F, Dragun, D, Neumayer, H-H, and Budde, K (2004): Reports of large immunosuppression trials in kidney transplantation: Room for improvement, Am.J.Transpl..

[51] Guyatt, G. H.; Sackett, D. L. und Cook, D. J. (1994): Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group, JAMA (Band 271), Nr. 1, Seite 59-63. URL: PM:8258890

[52] Fritsche, L.; Greenhalgh, T.; Falck-Ytter, Y.; Neumayer, H. H. und Kunz, R. (2002): Do short courses in evidence based medicine improve knowledge and skills? Validation of Berlin questionnaire and before and after study of courses in evidence based medicine, BMJ (Band 325), Nr. 7376, Seite 1338-1341. URL: PM:12468485

[53] Ellis, J.; Mulligan, I.; Rowe, J. und Sackett, D. L. (1995): Inpatient general medicine is evidence based. A-Team, Nuffield Department of Clinical Medicine, Lancet (Band 346), Nr. 8972, Seite 407-410. URL: PM:7623571

[54] Smith, R. (1991): Where is the wisdom...?, BMJ (Band 303), Nr. 6806, Seite 798-799. URL: PM:1932964

[55] White, K. L. (1995): Evidence-based medicine, Lancet (Band 346), Nr. 8978, Seite 837-838. URL: PM:7674753

[56] Kasiske, B. L.; Cangro, C. B.; Hariharan, S.; Hricik, D. E.; Kerman, R. H.; Roth, D.; Rush, D. N.; Vazquez, M. A. und Weir, M. R. (2002): The evaluation of renal transplantation candidates: clinical practice guidelines, Am.J.Transplant. (Band 1 Suppl 2), Seite 1-95. URL: PM:12108435

[57] (2000): European Best Practice Guidelines for Renal Transplantation (part 1), Nephrol.Dial.Transplant. (Band 15 Suppl 7), Seite 1-85. URL: PM:11286185

[58] Fritsche, L.; Budde, K. und Neumayer, H. H. (2003): Evaluating candidates for kidney transplantation: some recommendations still lack convincing clinical evidence, Nephrol.Dial.Transplant. (Band 18), Nr. 3, Seite 621-622. URL: PM:12584294

[59] Fritsche, L.; Vanrenterghem, Y.; Nordal, K. P.; Grinyo, J. M.; Moreso, F.; Budde, K.; Kunz, R.; Meyerrose, B. und Neumayer, H. H. (2000): Practice variations in the evaluation of adult candidates for cadaveric kidney transplantation: a survey of the European Transplant Centers, Transplantation (Band 70), Nr. 10, Seite 1492-1497. URL: PM:11118096

[60] Fritsche, L.; Nordal, K. P.; Vanrenterghem, Y.; Grinyo, J. M.; Moreso, F.; Budde, K. und Neumayer, H. H. (2000): Different diagnostic approaches to adult candidates for cadaveric kidney transplantation in Europe, Transpl.Int. (Band 13 Suppl 1), Seite S263-S266. URL: PM:11112009

[61] Einecke, G.; Mai, I.; Fritsche, L.; Slowinski, T.; Waiser, J.; Glander, P.; Bohler, T.; Neumayer, H. H. und Budde, K. (2003): Cyclosporin C2hour monitoring after renal transplantation, Int.J.Clin.Pharmacol.Ther. (Band 41), Nr. 10, Seite 477-481. URL: PM:14703954

[62] Fritsche, L.; Budde, K.; Dragun, D.; Einecke, G.; Diekmann, F. und Neumayer, H. H. (2004): Testosterone concentrations and sirolimus in male renal transplant patients, Am.J.Transplant. (Band 4), Nr. 1, Seite 130-131. URL: PM:14678044

[63] Sacristan, J. A.; Soto, J.; Galende, I. und Hylan, T. R. (1998): Randomized database studies: a new method to assess drugs' effectiveness?, J.Clin.Epidemiol. (Band 51), Nr. 9, Seite 713-715. URL: PM:9731918

[64] Byar, DP; Simon, RM; Freidewald, WT; Schlesslman, JJ; DeMets, DL; Ellenberg, JH; Gail, MH und Ware, JH (1976): Randomized clinical trials. Perspectives on some recent ideas, N.Engl.J.Med. (Band 295), Seite 74-80.


[Seite 32↓]

[65] Canto, J. G.; Kiefe, C. I.; Williams, O. D.; Barron, H. V. und Rogers, W. J. (1999): Comparison of outcomes research with clinical trials using preexisting data, Am.J.Cardiol. (Band 84), Nr. 8, Seite 923-7, A6. URL: PM:10532512

[66] Rogers, W. J. (1994): What is the optimal tool to define appropriate therapy: the randomized clinical trial, meta-analysis, or outcomes research? Commentary, Curr.Opin.Cardiol. (Band 9), Nr. 4, Seite 401-403. URL: PM:7919583

[67] Chalmers, T. C.; Celano, P.; Sacks, H. S. und Smith, H., Jr. (1983): Bias in treatment assignment in controlled clinical trials, N.Engl.J.Med. (Band 309), Nr. 22, Seite 1358-1361. URL: PM:6633598

[68] Gray-Donald, K. und Kramer, M. S. (1988): Causality inference in observational vs. experimental studies. An empirical comparison, Am.J.Epidemiol. (Band 127), Nr. 5, Seite 885-892. URL: PM:3282432

[69] Temple, R. (1990): Problems in the use of large data sets to assess effectiveness, Int J.Technol.Assess.Health Care (Band 6), Nr. 2, Seite 211-219. URL: PM:2203699

[70] Hemminki, E. (1982): Problems of clinical trials as evidence of therapeutic effectiveness, Soc.Sci.Med. (Band 16), Nr. 6, Seite 711-712. URL: PM:7089606

]71] Gibbons, R. J.; Holmes, D. R.; Reeder, G. S.; Bailey, K. R.; Hopfenspirger, M. R. und Gersh, B. J. (1993): Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups, N.Engl.J.Med. (Band 328), Nr. 10, Seite 685-691. URL: PM:8433727

[72] Grines, C. L.; Browne, K. F.; Marco, J.; Rothbaum, D.; Stone, G. W.; O'Keefe, J.; Overlie, P.; Donohue, B.; Chelliah, N.; Timmis, G. C. und . (1993): A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group, N.Engl.J.Med. (Band 328), Nr. 10, Seite 673-679. URL: PM:8433725

[73] Zijlstra, F.; de Boer, M. J.; Hoorntje, J. C.; Reiffers, S.; Reiber, J. H. und Suryapranata, H. (1993): A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction, N.Engl.J.Med. (Band 328), Nr. 10, Seite 680-684. URL: PM:8433726

[74] Tiefenbrunn, A. J.; Chandra, N. C.; French, W. J.; Gore, J. M. und Rogers, W. J. (1998): Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2), J.Am.Coll.Cardiol. (Band 31), Nr. 6, Seite 1240-1245. URL: PM:9581714

[75] (1997): A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators, N.Engl.J.Med. (Band 336), Nr. 23, Seite 1621-1628. URL: PM:9173270

[76] Hunsicker, L. G. und Bennett, L. E. (1995): Design of trials of methods to reduce late renal allograft loss: the price of success, Kidney Int Suppl (Band 52), Seite S120-S123. URL: PM:8587274

[77] Hannaford, P. C. und Owen-Smith, V. (1998): Using epidemiological data to guide clinical practice: review of studies on cardiovascular disease and use of combined oral contraceptives, BMJ (Band 316), Nr. 7136, Seite 984-987. URL: PM:9550959


[Seite 33↓]

[78] Fleming, P. J.; Gilbert, R.; Azaz, Y.; Berry, P. J.; Rudd, P. T.; Stewart, A. und Hall, E. (1990): Interaction between bedding and sleeping position in the sudden infant death syndrome: a population based case-control study, BMJ (Band 301), Nr. 6743, Seite 85-89. URL: PM:2390588

[79] Dwyer, T.; Ponsonby, A. L.; Blizzard, L.; Newman, N. M. und Cochrane, J. A. (1995): The contribution of changes in the prevalence of prone sleeping position to the decline in sudden infant death syndrome in Tasmania, JAMA (Band 273), Nr. 10, Seite 783-789. URL: PM:7861572

[80] Abenhaim, L.; Moride, Y.; Brenot, F.; Rich, S.; Benichou, J.; Kurz, X.; Higenbottam, T.; Oakley, C.; Wouters, E.; Aubier, M.; Simonneau, G. und Begaud, B. (1996): Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group, N.Engl.J.Med. (Band 335), Nr. 9, Seite 609-616. URL: PM:8692238

[81] Connolly, H. M.; Crary, J. L.; McGoon, M. D.; Hensrud, D. D.; Edwards, B. S.; Edwards, W. D. und Schaff, H. V. (1997): Valvular heart disease associated with fenfluramine-phentermine, N.Engl.J.Med. (Band 337), Nr. 9, Seite 581-588. URL: PM:9271479

[82] Waldman, R. J.; Hall, W. N.; McGee, H. und Van Amburg, G. (1982): Aspirin as a risk factor in Reye's syndrome, JAMA (Band 247), Nr. 22, Seite 3089-3094. URL: PM:7077803

[83] Belay, E. D.; Bresee, J. S.; Holman, R. C.; Khan, A. S.; Shahriari, A. und Schonberger, L. B. (1999): Reye's syndrome in the United States from 1981 through 1997, N.Engl.J.Med. (Band 340), Nr. 18, Seite 1377-1382. URL: PM:10228187

[84] Fritsche, L.; Horstrup, J.; Budde, K.; Reinke, P.; Giessing, M.; Tullius, S.; Loening, S.; Neuhaus, P.; Neumayer, H. H. und Frei, U. (2003): Old-for-old kidney allocation allows successful expansion of the donor and recipient pool, Am.J.Transplant. (Band 3), Nr. 11, Seite 1434-1439. URL: PM:14525606

[85] Kruger, B.; Zulke, C.; Fischereder, M.; Leingartner, T.; Kammerl, M.; Furst, A.; Graeb, C.; Anthuber, M.; Jauch, K. W. und Kramer, B. K. (2002): Early experience with the ET Senior Program "Old For Old"; better to be number one?, Transpl.Int (Band 15), Nr. 11, Seite 541-545. URL: PM:12461657

[86] Bererhi, Lynda; Flamant, Martin; Martinez, Frank; Karras, Alexandre; Thervet, Eric und Legendre, Christophe (1976): Rapamycin-induced oligospermia. [Letter], Transplantation September.15., 2003., Seite 885-886.

[87] Levy, G. A. (2001): C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation, BioDrugs. (Band 15), Nr. 5, Seite 279-290. URL: PM:11437692

[88] Ponticelli, C. (2001): Renal transplantation strengths and shortcomings, J.Nephrol. (Band 14 Suppl 4), Seite S1-S6. URL: PM:11798139

[89] Ray, J. G. (2002): Evidence in upheaval: incorporating observational data into clinical practice, Arch.Intern.Med. (Band 162), Nr. 3, Seite 249-254. URL: PM:11822916

[90] Coiera, E. W. (1996): Artificial intelligence in medicine: the challenges ahead, J.Am.Med.Inform.Assoc. (Band 3), Nr. 6, Seite 363-366. URL: PM:8930853

[91] Ohno-Machado, L. (1997): A comparison of Cox proportional hazards and artificial neural network models for medical prognosis, Comput.Biol.Med. (Band 27), Nr. 1, Seite 55-65. URL: PM:9055046

[92] Pesonen, E.; Eskelinen, M. und Juhola, M. (1996): Comparison of different neural network algorithms in the diagnosis of acute appendicitis, Int J.Biomed.Comput. (Band 40), Nr. 3, Seite 227-233. URL: PM:8666475

[93] Patil, S.; Henry, J. W.; Rubenfire, M. und Stein, P. D. (1993): Neural network in the clinical diagnosis of acute pulmonary embolism, Chest (Band 104), Nr. 6, Seite 1685-1689. URL: PM:8252942


[Seite 34↓]

[94] Reinus, W. R.; Wilson, A. J.; Kalman, B. und Kwasny, S. (1994): Diagnosis of focal bone lesions using neural networks, Invest Radiol. (Band 29), Nr. 6, Seite 606-611. URL: PM:8088968

[95] Baxt, W. G. (1991): Use of an artificial neural network for the diagnosis of myocardial infarction, Ann.Intern.Med. (Band 115), Nr. 11, Seite 843-848. URL: PM:1952470

[96] Baxt, W. G. und Skora, J. (1996): Prospective validation of artificial neural network trained to identify acute myocardial infarction, Lancet (Band 347), Nr. 8993, Seite 12-15. URL: PM:8531540

[97] Guerriere, M. R. und Detsky, A. S. (1991): Neural networks: what are they?, Ann.Intern.Med. (Band 115), Nr. 11, Seite 906-907. URL: PM:1952481

[98] Shortliffe, E. H. (1993): The adolescence of AI in medicine: will the field come of age in the '90s?, Artif.Intell.Med. (Band 5), Nr. 2, Seite 93-106. URL: PM:8358494

[99] Bates, D. W. und Gawande, A. A. (2003): Improving safety with information technology, N.Engl.J.Med. (Band 348), Nr. 25, Seite 2526-2534. URL: PM:12815139


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
01.09.2004